Primary thrombocythemia: Diagnosis and therapy;Primäre thrombozythämie: Diagnose und therapie

Medizinische Klinik

Volumn 101, Issue 8, 2006, Pages 624-634

  Petrides, Petro E ^a,b  

^a Hämatologisch Onkologische Schwerpunktpraxis und Tagesklinik   (Germany)

^b NONE   (Germany)

Author keywords

Anagrelide; ANAHYDRET; Aspirin; Hydroxyurea; Interferon ; JAK2 V617F mutation; Primary thrombocythemia; PT1

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; ANTITHROMBOCYTIC AGENT; BUSULFAN; HYDROXYUREA; JANUS KINASE 2; LACTASE; LALUK; PEGINTERFERON ALPHA2B; PHENYLALANINE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; SYREA; THROMBOREDUCTIN; VALINE;

ACUTE LEUKEMIA; BLEEDING; BLEEDING TENDENCY; BLOOD SMEAR; BLOOD TOXICITY; BONE MARROW; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; EDEMA; GASTROINTESTINAL SYMPTOM; GENE; GENE MUTATION; HEART PALPITATION; HUMAN; JAK2 GENE; LACTOSE INTOLERANCE; LEUKEMIA; MYELOFIBROSIS; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SYMPTOM; TACHYCARDIA; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTE STRUCTURE; THROMBOCYTHEMIA; THROMBOEMBOLISM;

ADULT; AGED; ASPIRIN; BIOLOGICAL RESPONSE MODIFIERS; CHILD; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; MALE; MUTATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PRIMARY PREVENTION; PROSPECTIVE STUDIES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; RISK FACTORS; THROMBOCYTHEMIA, HEMORRHAGIC; TIME FACTORS;

EID: 33747047793     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-006-1092-y     Document Type: Review

References (45)

1. Epstein E, Kretz J. Über einen Fall von hochgradiger Thrombocytenvermehrung. Klin Wochenschr 1930;9:1177-8.
2. Mesa RA, Silverstein MN, Jacobson SJ, et al. Population based evidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County study, 1976-1995. Am J Hematol 1999;61:10-5.
3. Falcetta R, Sacerdote C, Bazzan M, et al. Occupational and environmental risk factors in essential thrombocythemia: a case control study. G Ital Lav Ergon 2003;25:Suppl:9-12.
4. Goerttler PS, März E, Johansson PL, et al. Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-mpl protein expression and PRV-1 mRNA levels. Haematologica 2005;90:851-3.
5. Axelrad AA. Growth factor signaling in polycythemia vera cells: specific hypersensitivities to cytokines in the chronic myeloproliferative disorders. In: Petrides PE, Pahl HL, eds. Molecular basis of chronic myeloproliferative disorders. Heidelberg-New York: Springer, 2004:65-73.
6. James C, Ugo V, Casadevall N, et al. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific progress. Trends Mol Med 2005;11:546-54.
7. Tenedini E, Fagioloi ME, Vianelli N, et al. Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. Blood 2004;104:3126-35.
8. Moliterno AR, Williams DM, Gutierrez-Alamillo LI, et al. Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci U S A 2004;101:11444-7.
9. Petrides PE. Towards a molecular classification of chronic myeloproliferative disorders. In: Petrides PE, Pahl HL, eds. Molecular basis of chronic myeloproliferative disorders. Heidelberg-New York: Springer, 2004:3-9.
10. Thiele J, Kvasnicka H. Chronic myeloproliferative disorders: a pathologist's view. In: Petrides PE, Pahl HL, eds. Molecular basis of chronic myeloproliferative disorders. Heidelberg-New York: Springer, 2004:15-27.
11. Thiele J, Kvasnicka H. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 2003;82:148-52.
12. Florena AM, Tripodi C, Iannitto E, et al. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica 2004;89:911-9.
13. Regev A, Stark P, Blickstein D, et al. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol 1997;56:168-72.
14. 9/L. Haematologica 2000;85:492-5.
15. Lengfelder E, Hochhaus A, Kronawitter U, et al. Should a platelet limit of 600,000/μl be used as a diagnostic criterium in essential thrombocythemia? An analysis of the natural course including early stages. Br J Haematol 1998;100:15-23.
16. Petrides PE, Gisslinger H. CMPE 2004: aktuelle Empfehlungen zu Diagnostik und Therapie chronisch myeloproliferativer Erkrankungen. München: Gesellschaft zur Erforschung chronisch myeloproliferativer Erkrankungen, 2004.
17. Cortelazzo S, Viero P, Finazzi G. et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990;8:556-62.
18. Petrides PE, Siegel F. Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles. Blood Cells Mol Dis 2006;36:379-84.
19. Cervantes F, Alvarez-Larrán A, Talarn C, et al. Myelofibrosis with myeloid metaplasia following essential thrombocythemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 2002;118:786-90.
20. Kröger N, Zabelina T, Schieder H, et al. Pilot study of reduced intensity conditioning followed by allogenic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005;128:690-7.
21. Cortelazzo S, Marchetti M, Orlando E, et al. Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipoxygenase pathway. Am J Hematol 1998;57:277-82.
22. Petrides PE. Anagrelid: Pharmakologie und klinische Anwendung. Arzneimitteltherapie 2004;22:225-35.
23. Petrides PE. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia. Exp Opin Pharmacother 2004;5:1781-98.
24. Petrides PE: Anagrelide: what was new in 2004 and 2005? Semin Thromb Hemost 2006;32:399-408.
25. Steurer M, Gastl G, Jedezejczak WW, et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 2004;101:2239-46.
26. Storen EC, Tefferi A. Long term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97:863-6.
27. Mazzuconi MG, Redi R, Bernasconi S, et al. A long term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica 2004;89:1306-13.
28. Fruchtman SM, Petitt RM, Gilbert HS, et al., Anagrelide Study Group. Anagrelide: analysis of long term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res 2005;29:481-91.
29. Siegel F, Petrides PE. Efficacy and safety of anagrelide in 30 patients treated up to 14.8 years. Onkologie 2005;28:Suppl:81-2.
30. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol 2003;74:26-31.
31. Nand S, et al. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Am J Hematol 1996;52:46-50.
32. Furgerson JL, Vukelja SJ, Baker WJ, et al. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. Am J Hematol 1996;51:137-40.
33. Sterkers Y, Preudhomme C, Lai J-L, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91:616-22.
34. Weinfeld A, Swolin B, Westin J. Acute leukemia after hydroxyurea therapy in polycythemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Hematol 1994;52:134-9.
35. Finazzi G, Ruggeri M, Rodeghiero F, et al. Efficacy and safety of long term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood 2003;101:3749.
36. Langer C, Lengfelder E, Thiele J, et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica 2005;90:1333-8.
37. Samuelsson J, Hasselbalch H, Bruserud O, et al. A phase II trial of pegylated interferon-2b therapy for polycythemia vera and essential thrombocythemia. Cancer 2006;106:2397-405.
38. Cortelazzo S, Ginazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-6.
39. Harrison C, Campbell P, Buck G, et al. Hydroxyurea compared with anagrelide in high risk essential thrombocythemia. N Engl J Med 2005;353:33-45.
40. Petrides PE. The anagrelide hydroxyurea controversy in Europe. Presented at the 3rd International Conference on Chronic myeloproliferative Disorders. Rotterdam, March 31 to April 2, 2006.
41. Campbell P, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2 V617F mutation status. Lancet 2005;366:1945-53.
42. ANAHYDRET Study. Interim results as of June 24, 2005 (AOP, www.anahydret.at).
43. Kratz CP, Abd El-Monheim A, Manke EM, et al. Retrospective analysis of the clinical course of 12 children given the diagnosis essential thrombocythemia. Klin Pädiatr 2004;216:349-55.
44. Grieshammer M, Grünewald, M, Michiels JJ. Acquired thrombophilia in pregnancy: essential thrombocythemia. Semin Thromb Hemost 2003;29:205-12.
45. Petrides PE. Entdeckung der JAK2-Mutation. In|fo| Onkologie 2005;8:263-5.